Questions surrounding how biosimilars are tested and approved persist, yet they remain a potential tool for cutting health care costs.
It is important that pharmacists are aware of the federal and state laws governing medications that fall into this category.
Testing drugs for biological equivalence is the only way to determine
that they are safe and effective alternatives to brand-name
pharmaceuticals.
Kathleen Jaeger discusses current issues affecting the generic drug industry, including the Hatch-Waxman Act, drug importation from Canada, and biogenerics.
The availability and utilization of generic alternatives to brand-name
drugs have had a significant effect on cost savings for health care
consumers.